26794930Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, Lusk CM, Oberg S, George DJThe Lancet. OncologyCarcinoma, Renal Cell; Everolimus; Indoles; Kidney Neoplasms; PyrrolesAdult; Aged; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Proportional Hazards Models; Sunitinib; Survival Analysis; Treatment OutcomeEverolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016 Mar; 17(3):378-388.Lancet Oncol2016-01-13T00:00:002016Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.prns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD000368Living Beings1341183530.294764AgedD000328Living Beings1578255770.254432AdultD002292Disorders1134250.717085Carcinoma, Renal CellD007680Disorders1406200.652811Kidney NeoplasmsD007211Chemicals & Drugs1343180.849938IndolesD004305Concepts & Ideas52019580.724084Dose-Response Relationship, DrugD008875Concepts & IdeasLiving Beings1473249570.258811Middle AgedD009367Concepts & IdeasProcedures34719320.670065Neoplasm StagingD005260Physiology1992444050.191167FemaleD006801Living Beings2262862810.130052HumansD008297Physiology1931408600.201617MaleD016016Concepts & Ideas3048570.817586Proportional Hazards ModelsD016896Concepts & Ideas101179490.402389Treatment OutcomeD009362Disorders26910560.715963Neoplasm MetastasisD011758Chemicals & Drugs621840.890788PyrrolesD016019Concepts & Ideas43415360.742907Survival AnalysisD016001Concepts & Ideas1482280.949739Confidence IntervalsD053208Concepts & Ideas3258590.818599Kaplan-Meier EstimateD00006833828400.97566EverolimusD004334Concepts & Ideas2609160.852414Drug Administration ScheduleD005500Procedures76836160.590107Follow-Up StudiesD009361Disorders2265510.854984Neoplasm InvasivenessD018572Concepts & Ideas25812030.792696Disease-Free SurvivalMedicineUniversity of ChicagoWalter M.StadlerWalter M. Stadler41.78927490000000-87.601250000000001904Stadler, Walter M.Professortrue1ProfessorProfessorAuthorship 8730550.1415580.1415581authors10.2523has subject area